Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7182680 | 0.91 | TSHR (0.41) | L3MBTL1LMNACFTRKMT2AMEN1 | |
| SCHEMBL7180466 | 0.90 | CETP (0.43) | LMNACFTRKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL7181107 | 0.89 | L3MBTL1 (0.42) | L3MBTL1LMNACFTRKMT2AMEN1 | |
| SCHEMBL7189114 | 0.89 | CETP (0.45) | LMNACFTRKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL7178304 | 0.89 | CETP (0.45) | LMNACFTRKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL7187160 | 0.89 | CETP (0.45) | LMNACFTRKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL7186592 | 0.89 | CETP (0.45) | LMNACFTRKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL6031070 | 0.88 | NPSR1 (0.43) | LMNACFTRKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL1138267 | 0.88 | KMT2A (0.42) | LMNACFTRKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL7179807 | 0.87 | LMNA (0.39) | L3MBTL1LMNACFTRKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017120743-A1 | SILICONE-COMPATIBLE COMPOUNDS | Henkel IP & Holding GmbH (DE) | 2017-07-20 | — | — | WO | disclosed |
| CN-1200943-C | Organometallic acyl-aryl phosphine | CIBA SC HOLDING AG (CH) | 2005-05-11 | — | — | CN | disclosed |
| US-6579663-B2 | Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-06-17 | — | — | US | disclosed |
| US-20020107413-A1 | Organometallic monoacylarylphosphines | WOLF JEAN-PIERRE (CH) | 2002-08-08 | — | — | US | disclosed |
| US-6399805-B2 | SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES | CIBA SPECIALTY CHEMICALS CORPORATION | 2002-06-04 | — | — | US | disclosed |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | CIBA SPECIALTY CHEMICALS CORP. | 2001-10-18 | — | — | US | disclosed |
| CN-1308081-A | Organometallic acyl-aryl phosphine | CIBA SC HOLDING AG (CH) | 2001-08-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107413-A1 | Organometallic monoacylarylphosphines | CBR1, NAF1, DHCR24 | L3MBTL1 302/4885LMNA 3241/4885CFTR 2596/4885 |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | NAF1, DHCR24, CBR1 | L3MBTL1 126/4885LMNA 3247/4885CFTR 3551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.